The estimated Net Worth of Jeff Marc Goldberg is at least $3.39 Million dollars as of 26 September 2019. Jeff Goldberg owns over 421,432 units of Akcea Therapeutics Inc stock worth over $3,391,376 and over the last 7 years Jeff sold AKCA stock worth over $0.
Sign up
Jeff Goldberg AKCA stock SEC Form 4 insiders trading
Jeff has made over 2 trades of the Akcea Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Jeff exercised 421,432 units of AKCA stock worth $2,933,167 on 26 September 2019.
The largest trade Jeff's ever made was exercising 421,432 units of Akcea Therapeutics Inc stock on 26 September 2019 worth over $2,933,167. On average, Jeff trades about 58,929 units every 22 days since 2018. As of 26 September 2019 Jeff still owns at least 186,647 units of Akcea Therapeutics Inc stock.
You can see the complete history of Jeff Goldberg stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jeff Goldberg's mailing address?
Jeff's mailing address filed with the SEC is C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN, TX, .
Insiders trading at Akcea Therapeutics Inc
Over the last 7 years, insiders at Akcea Therapeutics Inc have traded over $384,023 worth of Akcea Therapeutics Inc stock and bought 35,029,381 units worth $610,464,515 . The most active insiders traders include Pharmaceuticals Inc Ionis, Paula Soteropoulos und B Lynne Parshall. On average, Akcea Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $40,228,816. The most recent stock trade was executed by Pharmaceuticals Inc Ionis on 10 October 2020, trading 21,237,715 units of AKCA stock currently worth $385,464,527.
What does Akcea Therapeutics Inc's logo look like?
Complete history of Jeff Goldberg stock trades at Aeglea BioTherapeutics Inc und Akcea Therapeutics Inc
Akcea Therapeutics Inc executives and stock owners
Akcea Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Barbara Yanni,
Director -
Amber Salzman,
Director -
Joseph Iii Klein,
Director -
Michael J. Yang,
Director -
Pharmaceuticals Inc Ionis,
10% owner -
Michael F Mac Lean,
Chief Financial Officer -
Jeff Marc Goldberg,
Chief Operating Officer -
Louis O'dea,
Chief Medical Officer -
Paula Soteropoulos,
Chief Executive Officer -
Elaine Hochberg,
Director -
Edward M Fitzgerald,
Director -
Sandford D Smith,
Director -
Richard A Moscicki,
Director -
Sarah Boyce,
President -
Christopher Gabrieli,
Director -
Alex G. Howarth,
Chief Operating Officer -
B Lynne Parshall,
Director -
Kyle Jenne,
Chief Commercial Officer -
Michael Dennis Price,
Chief Financial Officer -
Damien Mc Devitt,
Chief Executive Officer -
Joshua F. Patterson,
General Counsel -
William T. Andrews,
Chief Medical Officer